Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

BI-2536

SKU: orb1224066

Description

A potent and selective inhibitor of PLK1 with IC50 of 0.83 nM; also weakly inhibits the activities of PLK2 and PLK3 (IC50=3.5 nM and 9.0 nM, respectively), displays >1,000-fold selectivity to a panel of 63 other protein kinases; causes a mitotic arrest and induces apoptosis in human cancer cell lines, inhibits growth of human tumor xenografts in nude mice and induces regression of large tumors with well-tolerated intravenous dose regimens; also inhibits BRD4 with IC50 of 25 nM.Blood Cancer Phase 2 Clinical(In Vitro):Exceeding a 100-fold concentration range starting at 10 nM, BI 2536 causes HeLa cells to accumulate with a 4N DNA content, indicative of a cell-cycle block in either G2 phase or mitosis. In addition to HeLa cells, BI 2536 potently inhibits the proliferation of a panel of 32 human cancer cell lines, representing diverse organ derivations (including carcinomas of the breast, colon, lung, pancreas, and prostate, melanomas, and hematopoietic cancers) and varied patterns of tumor suppressor or oncogene mutations (including RB1, TP53, PTEN, andKRAS status). The half-maximal effective concentration (EC50) values in this cell panel ranged 2-25 nM, whereas a concentration of 100 nM of BI 2536 is typically sufficient for inducing a complete mitotic arrest. The proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells is blocked at EC50values ranging 12-31 nM, indicating a comparable sensitivity of cycling nontransformed cells to BI 2536.(In Vivo):BI 2536 (40-50 mg/kg, i.v.) blocks the growth of human cancer xenografts in immunodeficient, nu/nu mice. Consecutive cycles of 40-50 mg/kg BI 2536 given i.v. once or twice per week are found to be highly efficacious in diverse xenograft models, such as the HCT 116 colon cancer with complete tumor suppression with the twice per week schedule (treated versus the control (T/C) value 0.3%) and a T/C value of 16% with once per week treatment; both schedules are well-tolerated, as judged by clinical signs and absence of major body-weight changes.

Images & Validation

Key Properties

CAS Number755038-02-9
MW521.6544
Purity>98% (HPLC)
FormulaC28H39N7O3
SMILESO=C(NC1CCN(C)CC1)C2=CC=C(NC(N=C3N(C4CCCC4)[C@@H]5CC)=NC=C3N(C)C5=O)C(OC)=C2
TargetPLK
Solubility10 mM in DMSO

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

BI 2536 | BI2536

Similar Products

  • BI-2536 [orb1301011]

    >97%

    755038-02-9

    521.67

    C28H39N7O3

    25 mg, 5 mg
  • BI-4834 [orb1741017]

    876371-13-0

    593.76

    C32H47N7O4

    50 mg, 100 mg, 25 mg
  • BI-2536 monohydrate [orb2815427]

    876126-71-5

    539.67

    C28H41N7O4

    10 mg, 50 mg
  • (S)-BI 2536 [orb2564725]

    1241725-90-5

    521.65

    C28H39N7O3

    50 mg, 100 mg, 25 mg
  • PLK1/BRD4-IN-2 [orb2565464]

    2251709-89-2

    492.61

    C27H36N6O3

    10 mg, 50 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Protocol Information

Available Sizes

Select a size below

200 mg
500 mg
2 mg
$ 100.00
5 mg
$ 140.00
25 mg
$ 200.00
50 mg
$ 310.00
100 mg
$ 530.00